Actinium Pharmaceuticals Announces Rights Offering
01 févr. 2018 16h05 HE
|
Actinium Pharmaceuticals
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as...
Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs
08 janv. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Dr. Ludwig brings over 20 years of leadership and management expertise from Eli Lilly and Company and Imclone Systems, Inc. in oncology antibody therapeutics discovery and development where he...
Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting
12 déc. 2017 07h30 HE
|
Actinium Pharmaceuticals
Higher cell death observed with Actinium-225 labeled daratumumab with up to ten-fold higher potency as compared to naked daratumuambARC of Daratumumab-Actinium-225 labeled with high yield, high...
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M
11 déc. 2017 16h15 HE
|
Actinium Pharmaceuticals
Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for...
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
11 déc. 2017 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- TeneoBio, Inc. yesterday presented preclinical data on its lead therapeutic candidate, TNB-383B, a multivalent anti-BCMAxCD3 at the American...
Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
05 déc. 2017 07h30 HE
|
Actinium Pharmaceuticals
Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndromeTrial principal...
Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform
29 nov. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Poster presentation to detail results from ongoing Phase 2 trial for Actimab-A, Actinium’s CD33 targeting ARC or Antibody Radio-Conjugate, designed to explore Actimab-A’s efficacy in patients newly...
Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform
14 nov. 2017 08h00 HE
|
Actinium Pharmaceuticals
- AWE Program launched post successful demonstration of Actinium’s “Biobetter” capabilities as evidenced by superior experimental results with actinium-225 labeled daratumumab when compared to...
Actinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting Highlighting Company’s Drug Candidates and Technology Platform
01 nov. 2017 09h05 HE
|
Actinium Pharmaceuticals
Data from ongoing Actimab-A Phase 2 clinical trial highlighting efficacy, safety profile and clinical strategy as a single agent targeting CD33 in patients with AMLStudies highlighting enhanced...
Actinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid Leukemia
04 oct. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Phase 2 clinical trial is currently active at 16 clinical trial sites in the United States, surpassing the 10 clinical trial sites that were planned for the trial - Actinium affirms guidance for...